An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

Bron
International journal of gynecological cancer - ISSN 1048-891X-34:8 (2024) p. 1217-1224
Auteur(s)
    Rita Trozzi, Sandra Tuyaerts, Daniela Annibali, Alejandro Herreros Pomares, Lotte Boog, Peter André Van Dam, Karin Leunen, Christophe Deroose, Hans Trum, Frédéric Amant

XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant

Bron
Translational oncology - ISSN 1936-5233-43 (2024) p. 1-13
Auteur(s)

Quality of surgery and treatment and its association with hospital volume : a population-based study in more than 5000 Belgian ovarian cancer patients

Bron
European journal of surgical oncology - ISSN 0748-7983-50:3 (2024) p. 1-8
Auteur(s)
    Jolyce Bourgeois, Hanna M. Peacock, Isabelle Savoye, Cindy De Gendt, Roos Leroy, Geert Silversmit, Sabine Stordeur, Philippe de Sutter, Frederic Goffin, Mathieu Luyckx, Guy Orye, Peter André Van Dam, Toon Van Gorp, Leen Verleye

Treatment and outcomes in breast cancer patients : a cross section study from the EUSOMA breast centre network

Bron
European journal of cancer - ISSN 0959-8049-196 (2024) p. 1-6
Auteur(s)
    Cynthia Aristei, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Giuseppe Curigliano, Jakob De Vries, Donatella Santini, Francesco Sardanelli, Peter André Van Dam, Isabel Teresa Rubio